Vaderis Therapeutics closed an oversubscribed $152 million Series B financing while simultaneously initiating HEROIC, its global Phase III study of engasertib (VAD-044) for hereditary hemorrhagic telangiectasia. The company characterized engasertib as an oral, allosteric AKT inhibitor designed for HHT biology. The round was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, and existing investors Medicxi and Droia. Vaderis said it has no approved therapies for HHT globally and framed HEROIC as a pivotal step toward US regulatory approval. For the sector, the combination of cash runway plus Phase III launch highlights sustained investor appetite for genomics-anchored rare disease programs with clear regulatory intent.